Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were $-0.21.
Charming Shoppes Inc (CHRS)
Market is closed
Sector: Retail-Women's Clothing Stores
Hedge Fund Holdings
Filing Period:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Omega Advisors Leon Cooperman | 12,808,764 | $75,572,000 | +6% | 1.5% |
| 2. | Royce & Associates Chuck Royce | 4,715,821 | $27,823,000 | -14% | 0.08% |
| 3. | Crescendo Partners Eric Rosenfeld | 4,128,207 | $21,456,000 | 40.76% | |
| 4. | 20,000,000 | $18,875,000 | 0.05% | ||
| 5. | Buckingham Capital Management David Keidan | 3,084,500 | $18,199,000 | -10% | 1.36% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.30 | 47,600 | Large Shareholder | 5,893,736 | 2012-03-28 | Filing | |
| $5.64 | 385,000 | Large Shareholder | 5,846,136 | 2012-03-27 | Filing | |
| $5.20 | 91,900 | Large Shareholder | 5,461,136 | 2012-02-22 | Filing | |
| $5.22 | 200,000 | Large Shareholder | 5,369,236 | 2012-02-21 | Filing | |
| $3.50 | 25,000 | Officer | 40,637 | 2010-10-15 | Filing |
Institutional Investors' Holdings
News See All
Here’s Why Aristotle Small Cap Equity Strategy Sold Coherus BioSciences (CHRS)
Aristotle Capital Boston, LLC, an investment advisor, released its “Small Cap Equity Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Third Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Second Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Q1 2023 Earnings Call. Please be advised that today’s conference is being recorded.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to Coherus Biosciences Fourth Quarter and Fiscal Year 2022 Earnings Conference Call.
Should You Invest in Coherus BioSciences (CHRS)?
Scout Investments, an affiliate of Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” third quarter 2022 investor letter.
Will Coherus BioSciences (CHRS) Stock Bounce Back?
Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here.
10 Biotech Stocks to Buy Today According to Kerr Neilson's Platinum Asset Management
In this piece, we will take a look at the ten biotechnology stocks to buy today according to Kerr Neilson's Platinum Asset Management. If you want to skip the details about Mr.
10 Best Healthcare Stocks Under $20 According to Michael Castor's Sio Capital
In this article, we discuss the 10 best healthcare stocks under $20 according to Michael Castor's Sio Capital.
Billionaire Hedge Funds
